Table 1.

Chemotherapy for metastatic uveal melanoma⁸,⁷⁴,⁷⁷,⁸⁰,⁸¹,⁸⁵,⁸⁶

Lead author	Year	Number of patients	Chemotherapy	Median survival (months)	Response			Type of study
					CR	PR	%
Einhorn et al112	1974	25	Various	8.5	0	4	16	Retrospective
Rajpal et al110	1983	7*	Various	4.5				Retrospective
Gragoudas et al113	1991	61*	Various	3.8				Review
Pyrhonen et al114	1992	4	BOLD + interferon-α	–	0	2	50	Phase I
Kath et al115	1993	14*	Various	9	0	0	0	Retrospective
Nathan et al116	1994	16	Dartmouth	–	0	1	6	Prospective uncontrolled
Bedikian et al91	1995	143	Various	6	0	1	<1	Retrospective
Atzpodien et al117	1995	7#	Dacarbazine + carboplatin or Dartmouth + interferon-α2		–	–	–	Phase II
Albert et al85	1996	51	Various	4.5	0	0	0	Review
Proebstle et al118	1996	8	Dacarbazine + cisplatin + interferon-α2b	–	0	1	12	Phase I
Nathan et al119	1997	20	BOLD + interferon-α2b	–	0	4	20	Prospective uncontrolled
Flaherty et al92	1998	64	Dacarbazine or cisplatin	5	1	5	9	Prospective uncontrolled
Pyrhonen et al120	2002	20	BOLD + interferon-α	12	0	3	15	Prospective uncontrolled
Kivelä et al84	2003	24	BOLD + interferon-α2b	11	0	0	0	Prospective uncontrolled
Pfohler et al121	2003	14	Treosulfan + gemcitabine	14	1	3	29	Prospective uncontrolled
Bedikian et al122	2003	14	Temozolomide	7	0	0	0	Prospective uncontrolled
Schmittel et al89	2005	33	Gemcitabine + treosulfan	9	0	1	5	Phase I
Schmittel et al86	2006	19	Gemcitabine + treosulfan + cisplatin	7.7	0	1	0	Phase II
O’Neill et al90	2006	14	Dacarbazine + treosulfan	7.2	1	3	29	Phase II
Bedikian et al95	2008	4	Vincristine sulfate liposomal	9.6	1	2	31	Pilot
Homsi et al94	2010	22	Docosahexaenoic acid–paclitaxel	9.8	5	1	5	Phase II

Notes:

^*Treated with chemotherapy alone;

^#not segregated from cutaneous melanoma. Dartmouth refers to a regimen of dacarbazine + carmustine + cisplatin + tamoxifen.

Abbreviations: CR, complete response; PR, partial response; BOLD, bleomycin, vincristine, lomustine, and dacarbazine.